- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

INDIANAPOLIS, Dec. 1, 2015 /CNW/ -- New data from a completed Phase 3 trial show Trulicity ® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...

Add Yahoo as a preferred source to see more of our stories on Google. People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie ...

Two such prescription medications include dulaglutide (brand name Trulicity) and semaglutide (brand names Ozempic and Wegovy) ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

-- If approved, Lilly's GLP-1 receptor agonistwill provide type 2 diabetes patients a once-weekly treatment option in a single-dose, ready-to-use pen INDIANAPOLIS, Sept. 26, 2014 /PRNewswire/ -- The ...

Trulicity was late to the next-generation diabetes treatment party, so Eli Lilly ($LLY) knew its launch would have to be different. The traditional U.S. strategy ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...

-- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...